LUCIBRU 140 MG

Ibrutinib (Imbruvica) is a small molecule drug that binds permanently to a protein, Bruton’s tyrosine kinase (BTK), that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia, a form of non-Hodgkin’s lymphoma.

Description: Lucibru ibrutinib 140 mg is the official generic of Imbruvica 140 mg. Lucibru ibrutinib 140 mg is a prescription medicine used to treat people with::: Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL):: Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion::Waldenström’s macroglobulinemia (WM):: Mantle cell lymphoma (MCL) who have received at least one prior treatment:: Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment::For MCL and MZL, Lucibru ibrutinib 140 mg is approved on response. Data are not yet available to show if Lucibru ibrutinib 140 mg improves survival or symptoms::It is not known if Lucibru ibrutinib 140 mg is safe and effective in children.

Ibrutinib: Ibrutinib is a targeted therapy used to treat mantle cell lymphoma, another type of lymphoma called Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia. How ibrutinib works: Ibrutinib is a type of targeted therapy drug called a tyrosine kinase inhibitor. It works by blocking (inhibiting) signals within cancer cells that make them grow and divide. This may help to stop or slow down the cancer growing.